Antibody-Dependent Enhancement
"Antibody-Dependent Enhancement" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enhancement of viral infectivity caused by non-neutralizing antibodies. There are at least two mechanisms known to account for this: mediation by Fc receptors (RECEPTORS, FC) or by complement receptors (RECEPTORS, COMPLEMENT). Either the virus is complexed with antiviral IMMUNOGLOBULIN G and binds to Fc receptors, or virus is coated with antiviral IMMUNOGLOBULIN M and binds to complement receptors.
Descriptor ID |
D019067
|
MeSH Number(s) |
G06.920.095 G12.113
|
Concept/Terms |
Antibody-Dependent Enhancement- Antibody-Dependent Enhancement
- Antibody Dependent Enhancement
- Antibody-Dependent Enhancements
- Enhancement, Antibody-Dependent
|
Below are MeSH descriptors whose meaning is more general than "Antibody-Dependent Enhancement".
Below are MeSH descriptors whose meaning is more specific than "Antibody-Dependent Enhancement".
This graph shows the total number of publications written about "Antibody-Dependent Enhancement" by people in this website by year, and whether "Antibody-Dependent Enhancement" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 1 | 0 | 1 |
2011 | 1 | 0 | 1 |
2012 | 1 | 0 | 1 |
2014 | 0 | 1 | 1 |
2016 | 2 | 3 | 5 |
2017 | 6 | 3 | 9 |
2018 | 6 | 3 | 9 |
2019 | 1 | 0 | 1 |
2020 | 6 | 14 | 20 |
2021 | 1 | 4 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibody-Dependent Enhancement" by people in Profiles.
-
Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants. J Virol. 2021 09 09; 95(19):e0068521.
-
Immunopathogenesis of Different Emerging Viral Infections: Evasion, Fatal Mechanism, and Prevention. Front Immunol. 2021; 12:690976.
-
Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis. Mol Cells. 2021 Jun 30; 44(6):392-400.
-
Immunopathogenesis and immunobiology of SARS-CoV-2. Infez Med. 2021 Jun 01; 29(2):167-180.
-
The COVID-19 vaccine development: A pandemic paradigm. Virus Res. 2021 08; 301:198454.
-
The impact of COVID-19 vaccination campaigns accounting for antibody-dependent enhancement. PLoS One. 2021; 16(4):e0245417.
-
Antibody-Dependent Enhancement and the Critical Pattern of COVID-19: Possibilities and Considerations. Med Princ Pract. 2021; 30(5):422-429.
-
Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021 06; 21(6):382-393.
-
Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients. mSphere. 2021 02 24; 6(1).
-
Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. Front Immunol. 2021; 12:640093.